GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Debt-to-Equity

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Debt-to-Equity : 0.10 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Debt-to-Equity?

ImmuneOnco Biopharmaceuticals (Shanghai)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$70.42 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$11.37 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$818.46 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity or its related term are showing as below:

HKSE:01541' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01   Med: 0.02   Max: 0.1
Current: 0.1

During the past 3 years, the highest Debt-to-Equity Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) was 0.10. The lowest was -0.01. And the median was 0.02.

HKSE:01541's Debt-to-Equity is ranked better than
58.69% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:01541: 0.10

ImmuneOnco Biopharmaceuticals (Shanghai) Debt-to-Equity Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Debt-to-Equity Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
-0.01 0.02 0.10

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity -0.01 N/A 0.02 0.06 0.10

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity falls into.


ImmuneOnco Biopharmaceuticals (Shanghai) Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(70.415 + 11.37) / 818.461
=0.10

ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(70.415 + 11.37) / 818.461
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ImmuneOnco Biopharmaceuticals (Shanghai) Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Debt-to-Equity
Comparable Companies
HKSE:09966 HKSE:06660 HKSE:09969 HKSE:01952 HKSE:02105 HKSE:02315 HKSE:06955 HKSE:06855 HKSE:02696 HKSE:06826 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Gba Fund Investment Limited 2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Tian Wenzhi 2501 Other
Lav Immon Hong Kong Limited 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines